Hi Liz,
I am sorry to read of your horrible experiences with statins. I have had quite a scare just reading about the harm caused by statins (I have just been prescribed them and refuse to take them) and I am trying to create the sort of publicity so that the problems can be examined impartially.
in my opinion, it is not Q10 that the health service must provide to the people it places on statins, rather that the health service must stop prescribing statins in the first place. I have recently written to the minister for public health (Caroline Flint MP) and I am currently awaiting a reply. Whatever the reply, I will be using it as a basis to generate some dialogue in the national press.
Once I have received a reply to my letter, I will post the letter and the reply here. Perhaps you could interest your local paper in publishing your story. National papers have an arrangement for local journalists to pick up stories of national interest.
It is scandalous that large numbers of people are being prescribed these drugs, when the use of statins is predicated on questionable theories and methodologies. The recent abandonment of a phase 3 clinical trial that appeared to be killing more people than expected should help to provide the impetus to impose a global moratorium on the prescription of these drugs.
I was distressed to learn that statins are available as an over-the-counter (OTC) medication, in the UK. Iwas even more upset to learn that information concerning statin uptake and usage (purely from OTC purchases) was available from the following URL...
[http://www.leaddiscovery.co.uk/reports/OTC%20Statins%20-%20The%20UK%20Experience.html]
...but to read that information one has to pay a whopping $1900 for the privilege. So much for any freedom of information act! The quotation below is from the blurb giving reasons for purchasing the report.
(quote) "Given the low understanding of cholesterol and cardiovascular risk, a simple marketing message supported by a lifestyle modification programs is needed to sustain long-term use of OTC statins and to gain the endorsement of the switch from other stakeholders."(unquote)
So you see, you are not a sick person to the drug companies, you are in need of a simple marketing message to "SUSTAIN THE LONG-TERM USE OF STATINS" (my emphasis)
The link to other 'related reports' is, sadly, all too revealing, as evidenced by the price - $15200! Yes that's $74.50 for every precious page of a 204 page report entitled "Dyslipidemia - Statins Dominate Treatment Pathway".
The idea that you are an unwell person looking for help is not quite how you are viewed by the drug companies. I was incandescent after reading the blurb that one could read without paying the extortionate fee demanded and it bears reproducing in toto. vis.
(quote)
Introduction
Datamonitor estimates that there are 267m people in the seven major markets with total cholesterol >200mg/dL which is set to rise to 287m in 2015. Despite this vast patient potential, low diagnosis rates limit the market size, and with the launch of generic statins, and the maturing of the market, it is increasingly important for companies to target the under-treated dyslipidemia sub-populations.
Scope of this report
180 physician interviews carried out across the seven major pharmaceutical markets, plus the views of key industry opinion leaders
Examination of dyslipidemia patient potential, detailing the current and future prevalence of high total cholesterol
Detailed treatment trees to show dyslipidemia patient flows at country levels (US, Japan, France, Germany, Italy, Spain and the UK)
Expected future prescribing rates for combination therapy and new agents, such as Vytorin (ezetimibe + simvastatin) and atorvastatin and torcetrapib
[my note:] the last compound (atorvastatin combined with torcetrapib) has just been the subject of a phase 3 clinical trial, that had to be abandoned on December 2nd 2006 by Pfizer, because of an unexplained and unexpected raise in death rates! [end of my note]
Highlights of this report
Dyslipidemia patients are often plagued with risk factors and co-morbidities that increase their relative risk considerably. Datamonitor research found that a high percentage of patients with dyslipidemia also suffer from obesity, hypertension and type 2 diabetes, representing a potentially lucrative target.
[my note: you should understand that the only thing that you represent to the drug companies is that you are a potentially lucrative target]
The more aggressive approach to LDL lowering, and lower treatment thresholds recommended in updated guidelines means a greater patient population. However, increasing awareness in physicians and in the general population is essential to increase diagnosis and thus treatment rates.
[my note: I wonder where the push for more agressive treatment of LDL cholesterol is coming from... don't answer that, it was a rhetorical question and the answer is obvious]
Physicians predict that combination therapy will play an increasingly important role over the next three years. Given the highly competitive nature of the antidyslipidemic market, companies that can position novel products as effective treatments for use in combination therapy are likely to be the most successful.
[my note: to hell with does it work... just position novel treatments, eh?]
Reasons to Purchase this report
Gain independent insight into the management of dyslipidemia and understand what factors influence physicians' prescribing practices
Assess the future direction of dyslipidemia therapy, and the remaining unmet needs in order to successfully manage your developmental products
[my note: nothing here about understanding the risks or the harm caused by statins, that is already well documented in the medical literature... this recommendation to understand the factors which influence clinicians prescribing practices is, in my view not that far removed from subverting the physician's normal patient management.]
Identify lucrative new target populations in order to create new opportunities in this market.(unquote)
[my note: the current 'market' of 267million people is not enough but lucrative new target populations are being sought. The gravy train that is statin production has got to be stopped before we begin to see our children being prescribed statins for prophylactic reasons!]
regards,
xrn